Tamizaje neonatal para fibrosis quística en una muestra de la ciudad de Bogotá

dc.contributorMateus Arbelaez, Heidi Eliana
dc.contributorFonseca-Mendoza, Dora Janeth
dc.creatorAmado González, Paula
dc.date.accessioned2012-07-19T12:29:20Z
dc.date.available2012-07-19T12:29:20Z
dc.date.created2012-07-19T12:29:20Z
dc.date.issued2011
dc.identifierhttp://repository.urosario.edu.co/handle/10336/3616
dc.identifierhttps://doi.org/10.48713/10336_3616
dc.description.abstractCystic Fibrosis is the most common autosomic recessive disease in caucasic population. The incidence in Colombia is still unknown, but previous studies at Universidad del Rosario have shown that it is relatively high . Objective: To establish the incidence of the disease on a newborn population from Bogota. Methods: 8.297 cordblood samples were analyzed. Three neonatal screening test protocols were compared: IRT/IRT, IRT/DNA and IRT/DNA/IRT. Results: The present study showed an incidence of 1 in 8.297 for Cystic Fibrosis in the population. Conclusions: Given the relatively high incidence observed in Bogota, Cystic Fibrosis Neonatal screening is advisable for the colombian population.
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherMaestría en Ciencias con Énfasis en Genética Humana
dc.publisherFacultad de medicina
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto completo)
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARÁGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización.
dc.sourceAlonso MJ, Heine-Sunyer D, Calvo M, Rosell J, Giménez J, Ramos MD, y cols. (2007) Spectrum of mutations in the CFTR gene in Cystic fibrosis patients of Spanish ancestry. Ann Hum Genet; 71: 194–201
dc.sourceAlper Ö. M, Wong L-J, Young S, Pearl M, Graham S, Sherwin J, Nussbaum E, Nielson D, Platzker A, Daviess Z, Lieberthal A, Chin T, Shay G, Hardy K, Kharrazi M. (2004) Identification of Novel and Rare Mutations in California Hispanic and African American Cystic Fibrosis Patients. HUMAN MUTATION Mutation in Brief; 24: 353-365
dc.sourceBarak A, Dulitzki M, Efrati O, Augarten A, Szeinberg A, Reichert N. (2004) Pregnancies and outcome in women with cystic fibrosis. IMAJ; 7: 95-98
dc.sourceBear, C. E., Li, C. H., Kartner, N., Bridges, R. J., Jensen, T. J., Ramjeesingh, M. y cols. (1992). Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell; 68(4), 809−818.
dc.sourceBobadilla J.L, Macek M, Fine J.P, Farrell P.M. (2002) Cystic Fibrosis: A Worldwide Analysis of CFTR Mutations.Correlation With Incidence Data and Application to Screening. Human Mutation; 19: 575-606
dc.sourceBoucher R.C. (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J.; 23(1):146-158.
dc.sourceBowling F.G, Watson A.R.A, Rylatt D.B, Elliot J.E, Bunch R.J, Bundesen P.G. (1987) Monoclonal antibody-based trypsinogen enzyme immunoassay for screening of neonates for CF. Lancet; i: 826–827.
dc.sourceBriel M, Greger R, Kunzelmann K. (1998) Cl- transport by cystic fibrosis transmembrane conductance regulator (CFTR) contributes to the inhibition of epitelial Na+ channels (ENaCs) in Xenopus oocytes co-expressing CFTR and ENaC. Journal of Physiology; 508.3: 825—836
dc.sourceCardoso H, Crispino B, Mimbacas A, Cardoso M.E. (2004) A low prevalence of cystic fibrosis in Uruguayans of mainly European descent. Genet Mol Res. 30;3(2):258-63.
dc.sourceCarrillo J.C.(1986) Detección de Hipotiroidismo Congénito en Colombia. Acta Pediátrica Colombiana; IV:(1);31-37
dc.sourceCastellani C, Bonizzato A, Cabrini G, Mastella G. (1997) Newborn screening strategy for cystic fibrosis: a field study in an area with high allelic heterogeneity. Acta Paediatr; 86: 497-502
dc.sourceHudson V.M. (2001) Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radical Biology and Medicine; 30: 1440-1461
dc.sourceJay L, Mateus H, Fonseca D, Restrepo C.M, Keyeux G. (2006) PCR-heterodúplex por agrupamiento: Implementación de un método de identificación de portadores de la mutación más común causal de fibrosis quística en Colombia. Colombia Medica; 37: 176-182
dc.sourceKammesheidt A, Kharrazi M, Graham S, Young S, Pearl M, Dunlop C, Keiles S. (2006) Comprehensive genetic analysis of the Cystic Fibrosis Transmembrane Conductance Regulator From Dried Blood Specimens - Implications For Newborn Screening. Genetics In Medicine; 8: 557-562
dc.sourceKerem B-S, Rommens J.M, Buchanan J.A, Markiewicz D, Cox T.K, Chakravarti A, Buchwald M, Tsui L-C. (1989) Identification of the Cystic Fibrosis Gene: Genetic Analysis. Science; 245: 1073-1079
dc.sourceKeyeux G, Rodas C, Gelvez N, Carter D. (2002) Possible migration routes into South America deduced from mitochondrial DNA studies in Colombian Amerindian populations. Hum Biol.; 74(2):211-33.
dc.sourceKeyeux G, Rodas C, Bienvenu T, Garavito P, Vidaud D, Sanchez D, Kaplan J-C, Aristizabal G. (2003) CFTR Mutations in Patients from Colombia: Implications for Local and Regional Molecular Diagnosis Programs. Human Mutation; 22: 259-268
dc.sourceKleven D.T, McCudden C.R, Willis M.S (2008) Cystic fibrosis: newborn screening in America. Medical Laboratory Observer; 40: 16-27
dc.sourceKloosterboer M, Hoffman G, Rock M, Gershan W, Laxova A, Li Z, Farrell P.M. (2009) Clarification of Laboratory and Clinical Variables That Influence Cystic Fibrosis Newborn Screening With Initial Analysis of Immunoreactive Trypsinogen. Pediatrics; 123 (2): e338 -e346
dc.sourceKreindler J.L. (2010) Cystic fibrosis: Exploiting its Genetic Basis in the Hunt for New Therapies. Pharmacology & Therapeutics; 125: 219–229
dc.sourceLandsteiner K. (1905) Darmverschluss durch eingedicktes Meconium. Pankreatitis. Centr. Allg. Pathol.;16: 903–907
dc.sourceLöhr J.M, Hummel F.M, Pirilis K.T, y cols. (2009) Properties of different pancreatin preparations used in pancreatic exocrine insufficiency. Eur J Gastroenterol Hepatol; 21(9): 1024-1031
dc.sourceLayer P, Keller J, Lankisch P.G. (2001) Pancreatic enzyme replacement therapy. Curr Gastroenterol Rep.;3(2):101-108.
dc.sourceLesser J. (2006) La Negociación del Concepto de Nación en un Brasil Étnico: Los Inmigrantes Sirio-Libaneses y Nikkei y la Reestructuración de la Identidad Nacional. In: Wehr, Ingrid, editor. Un Continente en Movimiento: Migraciones en América Latina. Madrid, Spain: Editorial Iberoamericana; p. 19-38.
dc.sourceLi L, Zhou Y, Bell C.J, Earley M.C, Hannon W.H, Mei J.V (2006) Development and Characterization of Dried Blood Spot Materials for the Measurement of Immunoreactive Trypsinogen. J Med Screen; 13:79-84
dc.sourceLima Leâo L, Burle de Aguiar M.J. (2008) Newborn screening: what pediatricians should know. Jornal de Pediatria; 84 (4 Suppl): S80-90
dc.sourceLiou T.G, Rubenstein R.C. (2009) Carrier Screening, Incidence of Cystic Fibrosis, and Difficult Decisions. JAMA; 302:2595-2596
dc.sourceMaclean JE, Solomon M, Corey M, Selvadurai H (2011) Cystic fibrosis newborn screening does not delay the identification of cystic fibrosis in children with negative results. J Cyst Fibros.;10(5):333-337
dc.sourceMalcolm S. (1990) Recent Advances in the Molecular Analysis of Inherited Disease. Eur. J. Biochem; 194, 317-321
dc.sourceMassie R. J, Wilcken B, Van Asperen P, Dorney S, Gruca M, Wiley V, Gaskin K. (2000) Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels. J Pediatr.;137(2):214-220
dc.sourceMassie J, Curnow L, Tzanakos N, Francis I, Robertson C.F. (2006) Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing. Arch Dis Child.;91(3):222-225
dc.sourceMateus, H.E (2005) Identificación de mutaciones y correlación genotipo-fenotipo en pacientes colombianos afectados por Fibrosis Quística. Tesis de Grado Maestría Genética Humana. Universidad Nacional de Colombia.
dc.sourceMateus, H.E, Fonseca D.J, Sanchez L.S, Peñaloza I.F, Forero D.V, Perdomo P.A, Quiasua y cols. (2007) Frecuencia de la mutación F508del en estudiantes de la Facultad de Medicina de la Universidad del Rosario, Bogotá, Colombia. Colombia Médica. 38: 352-356
dc.sourceMayell, S. J, Munck, A, Craig J. V, Sermet, I, Brownlee, K. G, Schwarz, M. J, Castellani, C, Southern, K. W; European Cystic Fibrosis Society Neonatal Screening Working Group (2009) A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros; 8(1):71-78
dc.sourceMishra A, Greaves R, Smith K, Carlin J.B, Wootton A, Stirling R, Massie J. (2008) Diagnosis of cystic fibrosis by sweat testing: age-specific reference intervals. J Pediatr.;153(6):758-763
dc.sourceMogayzel P.J, Flume P.A. (2009) Update in Cystic Fibrosis 2009. Am J Repir Crit Care Med; 181: 539-544
dc.sourceOller A.M, Ramos M.D, JImenez J, Ghio A, Melano M, Rezzonico C.A, Marques I, Pereyro S, Casals T, Dodelson R. (2006) Mutational spectrum of cystic fibrosis patients from Córdoba province and its zone of influence: Implications of molecular diagnosis in Argentina. Molecular Genetics and Metabolism; 87: 370–375
dc.sourceMonestrol I, Klint A, Sparen P, Hjelte L. (2011) Age at diagnosis and disease progression of cystic fibrosis in an area without newborn screening. Paediatric and Perinatal Epidemiology, 25(3), 298–305
dc.sourceMontgomery J, Wittwer C. T, Kent J. O, Zhou L. (2007) Scanning the cystic fibrosis transmembrane conductance regulator gene using high-resolution DNA melting analysis. Clin Chem.;53(11): 1891-1898
dc.sourceMoskowitz S, Chmiel J, Sternen D, Cheng E, Cutting G. (2008) CFTR-Related Disorders. GeneReviews/NCBI/NIH/UW
dc.sourceNational Institutes of Health Consensus Development Conference Statement on genetic testing for cystic fibrosis. (1999) Genetic testing for cystic fibrosis. Arch Intern Med.;159 (14):1529-39.
dc.sourceNtimbane T, Comte B, Mailhot G, Berthiaume, Poitout V, Prentki M, Rabasa-Lhoret R, Levy E. (2008) Cystic Fibrosis-Related Diabetes: From CFTR Dysfunction to Oxidative Stress. Clin Biochem Rev.; 30: 153-169.
dc.sourceOrozco I, Velasquez R, Zielenski J, Tsui L.C, Chavez M, Lezana J.L y cols. (2000) Spectrum of CFTR mutations in Mexican cystic fibrosis patients: identification of five novel mutations (W1098C, 849delT, P750L, 4160insGGGG and 297-1G>A) Hum Genet; 106: 360-365
dc.sourceO`Sullivan B.P, Freedman S.D. (2009) Cystic fibrosis. Lancet; 373: 1891–904
dc.sourceOtt C.J, Blackledge N.P, Leir S-H, Harris A. (2009) Novel regulatory mechanisms for the CFTR gene. Biochemical Basis of Respiratory Disease ; 37: 843–848
dc.sourcePérez M, Luna M, Pivetta O, Keyeux G. (2006) CFTR gene analysis in Latin American CF patients: Heterogeneous Origin and Distribution of Mutations Across the Continent. Journal of Cystic Fibrosis; 6: 194-208.
dc.sourcePitt J. (2010) Newborn Screening. Clin Biochem Rev; 31: 57-68
dc.sourcePrice J. F. (2006) Newborn Screening for Cystic Fibrosis: Do we Need a Second IRT? Arch Dis Child.; 91(3): 209-210.
dc.sourceQuinton P.M. (1999) Physiological Basis of Cystic Fibrosis: A Historical Perspective. Physiological Reviews; 79: S3-S14
dc.sourceRestrepo C.M, Pineda L, Rojas-Martınez A, Gutierrez C.A, Morales A, Gomez Y, Villalobos M.C, Borjas L, Delgado W, Myers A, y Barrera-Saldana H.A. (2000) CFTR Mutations in Three Latin American Countries. American Journal of Medical Genetics; 91:277–279.
dc.sourceRaskin S, Pereira-Ferrari L, Reis F. C, Abreu F, Marostica P, Rozov T, Cardieri J, Ludwig N, Valentin L y cols. (2008) Incidence of cystic fibrosis in five different states of Brazil as determined by screening of p.F508del, mutation at the CFTR gene in newborns and patients. Journal of Cystic Fibrosis; 7: 15–22
dc.sourceRock M. J, Hoffman G, Laessig R. H, Kopish G. J, Litsheim T. J, Farrell P. M. (2005) Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. J Pediatr.; 147(3 Suppl): S73-77
dc.sourceRaskin S, Phillips J.A, Krishnamani M.R, Vnencak-Jones C, Parker R.A, Rozov T, y cols (1992) Cystic fibrosis genotyping by direct PCR analysis of Guthrie blood Sports. Am J Med Genet 1992; 46:665-669
dc.sourceRiordan J.R, Rommens J.M, Kerem Bat-Sheva, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou J.L, Drumm M.L, Iannuzzi M.C, Collins F.S, Tsui L.C (1989) Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complimentary DNA. Science; 245: 1066-1072
dc.sourceRodas C, Gelvez N, Keyeux G. (2003) Mitochondrial DNA studies show asymmetrical Amerindian admixture in Afro-Colombian and Mestizo populations. Hum Biol.; 75 (1):13-30.
dc.sourceRodrigues R, Gabetta C.S, Pedro K.P, Valdetaro F, Fernandez M, Magalâes P, Januario J, Maciel L. (2008) Cystic Fibrosis and Neonatal Screening. Cad. Saúde Pública, Rio de Janeiro; 24 Sup 4: S475-S484
dc.sourceRodríguez Z, Veloza L, Baena J, Ramos E, Gómez C, Gómez D. (2009) Parámetros Hematológicos de Pacientes con Fibrosis Quística de la Costa Caribe Colombiana: Análisis y Asociación con Aislamiento de Pseudomonas aeruginosa. Ciencias Biomédicas; 7: 92-102
dc.sourceRommens J.M, Ianuzzi M.C, Kerem B-S, Drumm M.L, Melmer G, Dean M, Rozmahel R, Cole J.L, Kennedy D, Hidaka N, Zsiga M, Buchwald M, Riordan J.R, Tsui L-C, Collins, F.S. (1989) Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping. Science; 245: 1059-1065
dc.sourceRottner M, Freyssinet J-M, Martinez M.C. (2009) Mechanisms of the noxious inflammatory cycle in cystic fibrosis. Respiratory Research; 10: 23
dc.sourceRoss L. F. (2008) Newborn Screening for Cystic Fibrosis: a Lesson in Public Health Disparities. J Pediatr.; 153(3): 308-313
dc.sourceRowe S. M, Miller S, Sorscher E.J. (2005) Cystic Fibrosis. N Engl J Med; 352: 1992-2001
dc.sourceRowntree R. K and Harris A. (2003) The Phenotypic Consequences of CFTR Mutations. Annals of Human Genetics; 67: 471–485
dc.sourceRyley H. C, Robinson P. G, Yamashiro Y, Bradley D. M. (1981) Assay of serum immunoreactive trypsin in dried blood spots and the early detection of cystic fibrosis. J Clin Pathol.; 34(8): 906-910
dc.sourceSánchez I, Pérez M.A, Boza M.L, Lezana V., Vila M.A, Repetto G y cols. (2001) Consenso Nacional de Fibrosis Quística. Rev Chil Pediatr.; 22(4): 356-380
dc.sourceSands D, Zybert K, Nowakowska A. (2010) Cystic fibrosis newborn screening enables diagnosis of elder siblings of recalled infants--additional benefit. Folia Histochemica et Cytobiologica; 48 (1): 163-165
dc.sourceSatizabal J.M, Erazo M.L, Solorzano M.C, Herrera E, Velez O, Lopez P. (2001) Tamizaje Neonatal de Hipotiroidismo Congénito en Colombia: ¿Qué muestra utilizar? Acta Biológica Colombiana; 6(2): 71-73
dc.sourceSouthern K.W, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J, et al. (2007) A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros; 6: 57–65
dc.sourceSchwiebert E.M, Benos D.J, Egan M.E, Stutts M.J, Guggino W.B (1999) CFTR is a conductance regulator as well as a chloride channel. Physiol Rev.;79(1 Suppl):S145-66
dc.sourceSikkens E.C.M, Cahen D.L, Kuipers E,J, Bruno M.J. (2010) Pancreatic enzyme replacement therapy in chronic pancreatitis. Best Practice & Research Clinical Gastroenterology; 24: 337-347
dc.sourceSims E.J., Clark A, McCormick J, Mehta G, Connett G, Mehta A. (2007) Cystic Fibrosis Diagnosed After 2 Months of Age Leads to Worse Outcomes and Requires More Therapy. Pediatrics; 119 (1); 19 -28
dc.sourceSontag M.K, Hammond K.B, Zielenski J, Wagener J.S, Accurso F.J. (2005) Two-Tiered Immunoreactive Trypsinogen-Based Newborn Screening For Cystic Fibrosis In Colorado: Screening Efficacy And Diagnostic Outcomes. J Pediatr; 147:S83-S88
dc.sourceSouthern K.W y Peckham D. (2004) Establishing a diagnosis of Cystic Fibrosis. Chronic Respiratory Disease; 1: 205–210
dc.sourceSouthern K.W, Mérelle M.M, Dankert-Roelse J.E, Nagelkerke A.D. (2009) Newborn screening for cystic fibrosis. Cochrane Database Syst Rev;(1):CD001402
dc.sourceSoultan Z. N, Foster M. M, Newman N. B, Anbar R. D. (2008) Sweat Chloride Testing in Infants Identified as Heterozygote Carriers by Newborn Screening. J Pediatr. ; 153(6): 857-859
dc.sourceStephan U, Busch E.W, Kollberg H, Hellsing K. (1975) Cystic fibrosis detection by means of a test strip. Pediatrics; 55: 35–38
dc.sourceSugarman E.A, Rohlfs E.M, Silverman L.M, Allitto B.A. (2004) CFTR mutation distribution among U.S. Hispanic and African American individuals: Evaluation in cystic fibrosis patient and carrier screening populations. Genetics in Medicine; 6: 392-399
dc.sourceTurnbull E.L, Rosser M, Cyr D.M. (2007) The role of the UPS in cystic fibrosis. BMC Biochemistry; 8: S1-S11
dc.sourceTsui L.-C., Buchwald M, Barker D, Braman J.C, Knowlton R, Schumm J.W, Eiberg H, Mohr J, Kennedy D, Plavsic N. (1985) Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science; 230: 1054–1057
dc.sourceVásquez C, Aristizábal R, Daza W. (2008) Fibrosis Quística en Colombia. www.neumologia-pediatrica.cl
dc.sourceWaqlkowiak J, Sands D, Nowakowska A, Piotrowski R, Zybert Katarzyna, Herzig K-H MIlanowski A. (2005) Early Decline of Pancreatic Function in Cystic Fibrosis Patients with Class 1 or 2 CFTR Mutations. Journal of Pediatric Gastroenterology and Nutrition; 40:199–201
dc.sourceWang W, Wu J, Bernard K, Li G, Wang G, Bevensee M. O, Kirk K. L. (2010) ATP-independent CFTR channel gating and allosteric modulation by phosphorylation. PNAS; 107: 3888-3893
dc.sourceCastellani C, Picci L, Tamanini A. (2009) Association Between Carrier Screening and Incidence of Cystic Fibrosis JAMA; 302:2573-2579
dc.sourceWatson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, y cols. (2004) Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004; 6: 387–391
dc.sourceWhitcomb D.C. (2010) Genetic Aspects of Pancreatitis. Annual Reviews; 61: 413-424
dc.sourceWilcken B. (2007) Newborn screening for cystic fibrosis: techniques and strategies. J Inherit Metab Dis; 30(4): 537-543
dc.sourceXu W.M, Chen J., Chen H., Diao R.Y, Fok K.L, Dong J.D y cols (2011) Defective CFTR-Dependent CREB Activation Results in Impaired Spermatogenesis and Azoospermia. PLoS ONE 6(5): e19120. doi:10.1371/journal.pone.0019120
dc.sourceZielenski J. (2000) Genotype and Phenotype in Cystic Fibrosis. Respiration; 67:117–133
dc.sourceCollazo T, Magarino C, Chavez R, Suardiaz B, Gispert S, Gomez M, Rojo M y cols. (1995) Frequency of delta-F508 mutation and XV2C/KM19 haplotypes in Cuban cystic fibrosis families. Hum Hered; 45: 55-57
dc.sourceComeau A.M, Accurso F.J, White T. B, Campbell P. W, Hoffman G, Parad R.B, Wilfond B. S, Rosenfeld M, Sontag M. K, Massie J, Farrel P. M, O´Sullivan B.P. (2007) Guidelines for Implementation of Cystic Fibrosis Newborn Screening Programs: Cystic Fibrosis Foundation Workshop Report PEDIATRICS: 119: e495-e519
dc.sourceCyr D.M. (2005) Arrest of CFTR F508 folding. Nature Structural & Molecular Biology; 12: 2-3
dc.sourceChakraborty R, Srinivasan M.R, Raskint S. (1993) Estimation of the Incidence of a Rare Genetic Disease through a Two-Tier Mutation Survey. Am.J. Hum. Genet; 52:1129-1138
dc.sourceChambers L.A, Rollins B.M, Tarran R. (2007) Liquid Movement Across the Surface Epithelium of Large Airways. Respir Physiol Neurobiol; 159(3): 256–270.
dc.sourceCrossley J.R, Elliott R.B, Smith P.A. (1979) Dried-blood spot screening for cystic fibrosis in the newborn. Lancet; 1:472–474
dc.sourceD´Alessandro V, Renteria F, Fernandez A, Martinez, M.I, Segal E. (2009) Comparación del estado clínico-funcional en niños con Fibrosis Quística detectados por pesquisa neonatal o por síntomas clínicos. Arch Argent Pediatr; 107(5):430-435
dc.sourceDa Paula A.C, Sousa M, Xu Zhe, Dawson E.S, Boyd A.C, Sheppard D.N, Amaral M.D. (2010) Folding and Rescue of a CFTR Trafficking Mutant Identified Using Human-Murine Chimeric Proteins. The Journal of Biological Chemistry; 285: 27033-27044
dc.sourceDankert-Roelse, Mérelle ME. (2005) Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe. J Pediatr; 147(3 Suppl):S15-20
dc.sourceDavis P.B. (2006) Cystic Fibrosis Since 1938. Am J Respir Crit Care Med; 173: 475–482
dc.sourceDawson K.P, Frossard P.M. (2000) The Geographic Distribution of Cystic Fibrosis Mutations Gives Clues About Population Origins. Eur J Pediatr; 159: 496-499
dc.sourceDe Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, Sinaasappel M. (2006) Cystic fibrosis: terminology and diagnostic algorithms. Thorax; 61: 627–635
dc.sourceDequeker E, Stuhrmann M, Morris M, Casals T, Castellani C, Claustres M, Cuppens H, des Georges M, Ferec C, Macek M, Pignatti P.F, Scheffer H, Schwartz M, Witt M, Schwarz M y Girodon E. (2009) Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders – updated European recommendations. European Journal of Human Genetics; 17:51–65
dc.sourcede Gracia J, Mata F, Alvarez A, Casals T, Gatner S, Vendrell M, de la Rosa D, Guarner L, Hermosilla E. (2005) Genotype-phenotype correlation for pulmonary function in CF Thorax; 60: 558–563
dc.sourceDi Sant’Agnese P. A., Darling R. C, Perera G. A y Shea E. (1953) Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas. Pediatrics; 12: 549–563
dc.sourceDu K, Sharma M y Lukac G.L. (2005) The F508 cystic fibrosis mutation impairs domaindomain interactions and arrests post-translational folding of CFTR. Nature Structural & Molecular Biology; 12: 17-25
dc.sourceDu M, Liu X, Welch E. M, Hirawat S, Peltz S. W, Bedwell D. M. (2008) PTC124 is an Orally Bioavailable Compound that Promotes Suppression of the Human CFTR-G542X Nonsense Allele in a CF Mouse Model. Proc Natl Acad Sci U S A.;105(6): 2064-2069
dc.sourceDurand J y Massey D.S. (2010) New World Orders: Continuities and Changes in Latin American Migration Ann Am Acad Pol Soc Sci.; 630(1): 20–52
dc.sourceFarber S. (1945) Some organic digestive disturbances in early life. J.Mich State. Med. Soc.; 44: 587–594
dc.sourceFarrell P.M, Rosenstein B.J, White T.B y cols. (2008) Guidelines for Diagnosis of Cystic Fibrosis in Newborns Through Older Adults: Cystic Fibrosis Foundation Consensus Report. J Pediatr; 153(2): S4-S14
dc.sourceFarrell P.M, Ksorok M.R, Rock M.J y cols. (2002) Lung disease in patients with cystic fibrosis diagnosed through neonatal screening or after delays associated with traditional methods. Pediatr Pulmonol; S24:319.
dc.sourceGadsby D.C, Vergani P, Csanády L. (2006) The ABC Protein Turned Chloride Channel Whose Failure Causes Cystic Fibrosis. Nature; 440: 477-483
dc.sourceGregg R.G, Wilfond B.S , Farrell P.M, Laxova A, Hassemer D, Mischlert E.H. (1993) Application of DNA Analysis in a Population-screening Program for Neonatal Diagnosis of Cystic Fibrosis (CF): Comparison of Screening Protocols. Am. J. Hum. Genet; 52: 616-626
dc.sourceGregg R.G, Simantel A, Farrell P.M, Koscik R, Kosorok M.R, Laxova A, Laessig R, Hoffman G, Hassemer D, Mischler E.H, Splaingard M. (1997)Newborn Screening for Cystic Fibrosis in Wisconsin: Comparison of Biochemical and Molecular Methods. PEDIATRICS; 99: 819-824
dc.sourceGrody W.W, Cutting G.R, Klinger K.W, Richards C.S, Watson M.S, Desnick R.J. (2001) Laboratory standards and guidelines for population based cystic fibrosis carrier screening. Genetics in Medicine; 3: 149-154
dc.sourceHammond K.B, Abman S.H, Sokol R.J, Accurso F.J. (1991) Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. N Engl J Med.;325(11): 769-774
dc.sourceHale J.E, Parad R.B, Comeau A.M. (2008) Newborn Screening Showing Decreasing Incidence of Cystic Fibrosis. NEJM; 358: 973-974
dc.sourceHuang P, Gilmore E, Kultgen P, Barnes P, Milgram S, Stutts M.J. (2004) Local Regulation of Cystic Fibrosis Transmembrane Regulator and Epithelial Sodium Channel in Airway Epithelium. Proc Am Thorac Soc; 1: 33–37
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectFibrosis quística
dc.subjectTamizaje neonatal
dc.subjectTripsinogeno
dc.subjectSangre de cordón umbilical
dc.titleTamizaje neonatal para fibrosis quística en una muestra de la ciudad de Bogotá
dc.typemasterThesis


Este ítem pertenece a la siguiente institución